key: cord-0696375-luskse48
authors: Cho, J. L.; Villacreses, R.; Nagpal, P.; Guo, J.; Pezzulo, A. A.; Thurman, A. L.; Hamzeh, N. Y.; Blount, R. J.; Fortis, S.; Hoffman, E. A.; Zabner, J.; Comellas, A. P.
title: Small Airways Disease is a Post-Acute Sequelae of SARS-CoV-2 Infection
date: 2021-05-30
journal: nan
DOI: 10.1101/2021.05.27.21257944
sha: 1ea87d293be6c20001de9bb292cc4e9dce851370
doc_id: 696375
cord_uid: luskse48

Background The sequelae of SARS-CoV-2 infection on pulmonary structure and function remain incompletely characterized. Methods Adults with confirmed COVID-19 who remained symptomatic more than thirty days following diagnosis were enrolled and classified as ambulatory, hospitalized or requiring the intensive care unit (ICU) based on the highest level of care received during acute infection. Symptoms, pulmonary function tests and chest computed tomography (CT) findings were compared across groups and to healthy controls. CT images were quantitatively analyzed using supervised machine-learning to measure regional ground glass opacities (GGO) and image-matching to measure regional air trapping. Comparisons were performed using univariate analyses and multivariate linear regression. Results Of the 100 patients enrolled, 67 were in the ambulatory group. All groups commonly reported cough and dyspnea. Pulmonary function testing revealed restrictive physiology in the hospitalized and ICU groups but was normal in the ambulatory group. Among hospitalized and ICU patients, the mean percent of total lung classified as GGO was 13.2% and 28.7%, respectively, and was higher than in ambulatory patients (3.7%, P<0.001). The mean percentage of total lung affected by air trapping was 25.4%, 34.5% and 27.2% in the ambulatory, hospitalized and ICU groups and 7.3% in healthy controls (P<0.001). Air trapping measured by quantitative CT correlated with the residual volume to total lung capacity ratio (RV/TLC; {rho} =0.6, P<0.001). Conclusions Air trapping is present in patients with post-acute sequelae of COVID-19 and is independent of initial infection severity, suggesting obstruction at the level of the small airways. The long-term consequences are not known.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, primarily infects the respiratory tract and causes a wide range of disease severity, including respiratory failure due to the acute respiratory distress syndrome (ARDS) 1 . Survivors of severe COVID-19 have pulmonary function abnormalities that persist for weeks to months after resolution of the acute illness 2,3 . Additionally, interstitial changes are frequently observed on lung imaging following severe infection. These findings are consistent with literature on the long-term respiratory sequelae of ARDS 4, 5 and observations from previous severe coronavirus outbreaks 6, 7 .

Early reports of post-acute sequelae of COVID-19 (PASC), or "long COVID", suggest that respiratory symptoms, including cough and dyspnea, are common among COVID-19 survivors and that they occur in a significant proportion of patients who experienced mild infection not requiring hospitalization 8, 9 . The long-term effects of SARS-CoV-2 infection in these patients are poorly understood, but the potential impact on our healthcare systems is enormous given the millions of infections worldwide, most of whom had mild disease. The primary aim of this study was to characterize the effects of SARS-CoV-2 on pulmonary structure and function in the postacute period. Specifically, we sought to determine whether respiratory symptoms, pulmonary function or radiographic abnormalities varied based on the severity of acute infection.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ;  https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint laboratory testing, pulmonary function testing and chest imaging on the day of their clinic visit as part of the clinical protocol. Pulmonary function testing and chest CT data was compared to a cohort of healthy non-smoking control subjects (Supplementary Appendix), who were matched to post-COVID-19 patients based on age, sex and ethnicity (Table S1) . We prespecified that analysis would be performed after the first 100 patients were consented.

Patients and healthy subjects underwent non-contrast chest CT with an inspiratory scan coached to total lung capacity (TLC) and an expiratory scan coached to residual volume (RV).

The scanning protocol for all subjects was standardized as previously described and adhering to the principles outlined by the Quantitative Imaging Biomarker Alliance 12, 13 . Qualitative CT image analysis was performed by an experienced, blinded radiologist (P.N.). CT images were also quantitatively analyzed using texture analysis (Adapted Multiple Feature Method; AMFM) and

Disease Probability Measure (DPM, VIDA Diagnostics). These machine-learning-and imagematching-based approaches are detailed in the Supplementary Appendix 12, [14] [15] [16] [17] [18] [19] . Briefly, the AMFM-based texture analysis quantifies ground glass opacities (GGO) as a percent of total lung volume at TLC by utilizing grayscale patterns within CT images. DPM quantifies the voxel-tovoxel difference in Hounsfield Units (HU) between matched inspiratory and expiratory images to estimate the probability of air trapping such that the probability is inversely proportional to the relative differences in HU 19 . When quantified using DPM analysis, air trapping reflects functional small airways disease (fSAD) 19-21 .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Analyses were pre-specified to determine whether there were differences across the ambulatory, hospitalized and ICU groups and between the ambulatory group and healthy controls. Univariate comparisons were made using the Chi-squared test, one-way ANOVA or the Mann-Whitney test; the Kruskal-Wallis test was used to correct for multiple comparisons across groups. Multivariable linear regression was used to adjust for age and body mass index (BMI) and the least square means were calculated; correction for multiple comparisons across groups was performed using Tukey's test. Spearman's correlation coefficients were used to assess the strength of association between pairs of predefined variables. In all cases, differences were considered statically significant when P was less than 0.05 based on a two-sided test. Statistical analyses were performed using GraphPad Prism or R statistical software (http://www.rproject.org).

Between June 2020 and January 2021, 110 patients were evaluated in the post-acute COVID-19 clinic and were eligible for enrollment. 101 individuals (91.8%) consented to participate. One patient was excluded because the diagnosis of COVID-19 could not be confirmed. Thus, 100 individuals were included in the analysis.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The demographic and clinical characteristics of the participants at baseline are shown in Table   1 . Most patients were treated in the ambulatory setting (67%) during the acute COVID-19 period. The median age of the patients was 48 years (IQR, 36.3 to 60.5 years) and 66% were female. Patients who were hospitalized or in the ICU were significantly older than ambulatory patients (P<0.001 and P<0.01, respectively). At least one co-existing illness was present in 76 patients. Obesity (59%) and hypertension (27%) were the most common co-existing illnesses.

Critically ill patients were more likely to have chronic kidney disease, chronic obstructive pulmonary disease, type 2 diabetes mellitus and hypertension compared to ambulatory patients. The most common co-existing pulmonary disorder was asthma (26%), followed by chronic obstructive pulmonary disease (6%) and interstitial lung disease (4%). The majority of patients were never smokers (75%). Smoking was more common among hospitalized or ICU patients than ambulatory patients. Among former and current smokers, median pack-years 

The most common symptoms during acute COVID-19 infection were fatigue (83.7%), dyspnea (82.3%), and cough (71.4%) (Figure 1 , Table S2 ). The median length of admission was 4 days (IQR, 2.5-7) for the hospitalized group and 18.5 days (IQR, 10.8-42.3) for the ICU group (P<0.001). None of the ambulatory patients required supplemental oxygen during acute illness.

Ten (58.8%) of the hospitalized patients and all of the critically ill patients required . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S2 .

The most common treatments for COVID-19 were corticosteroids (36%), antibiotics (18%) and remdesivir (16%) ( Table S2) . Hospitalized and ICU patients were more likely than ambulatory patients to receive treatment with corticosteroids (64.7%, 87.5% and 16.4%, respectively; P<0.001 for both comparisons), remdesivir (29.4%, 68.8% and 0%; P<0.001 for both comparisons) and convalescent plasma (17.6%, 56.3% and 1.5%; P<0.05 and P<0.001, respectively). Two patients each in the ambulatory (3%) and hospitalized (11.8%) groups and one patient (6.3%) in the ICU group experienced venous thromboembolism as a complication of acute SARS-CoV-2 infection. Additional complications, including the need for renal replacement therapy (12.5%), pneumothorax (6.3%) and the need for tracheostomy (18.8%) were observed in the ICU group.

Similar to acute infection, the most commonly reported persistent symptoms at follow-up were dyspnea (73%), fatigue (56%) and cough (34%) (Figure 1 , Table S3 ). At follow-up, two patients in the hospitalized group (11.8%) and 9 patients in the ICU group (56.3%) had an ongoing . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint requirement for supplemental oxygen that was not present prior to SARS-CoV-2 infection.

Additional clinical data for post-acute COVID-19 is provided in Table S3 .

The median score on the mMRC dyspnea scale at follow-up was 2 (IQR, 0-2) (Figure 1 , Table   S4 ). Compared to the ambulatory group (38.8%), a higher proportion of patients in the hospitalized (70.6%) and ICU (75%) groups had an mMRC score greater than or equal to 2 (P<0.01). The median percent predicted pre-bronchodilator forced vital capacity (FVC) and

forced expiratory volume in one second (FEV1) in post-acute COVID-19 patients were 95% (IQR 81-106) and 93% (IQR 78-104), respectively (Figure 2 ). Compared to the ambulatory group, the hospitalized and ICU groups had a lower FVC (P<0.01 and P<0.001, respectively) and FEV1 (P<0.05 and P<0.001, respectively). The FVC and FEV1 in ambulatory patients were not different compared to healthy controls. The median pre-bronchodilator FEV1/FVC was 0.8 (IQR, 0.76-0.84), and there were no differences across groups. No clinically significant response to bronchodilator was observed for FVC or FEV1 in any of the PASC groups. Median percent predicted total lung capacity (TLC) was 96% (IQR, 83.5-109) and median residual volume was 82% (IQR, 64.3-98.8) in PASC patients. Compared to ambulatory patients, hospitalized and critically ill patients had lower TLC (P<0.01 and P<0.001, respectively). Critically ill patients also had lower RV compared to ambulatory patients (P<0.01). TLC and RV were similar between the ambulatory group and healthy controls. The median percent predicted diffusing capacity for carbon monoxide (DLCO) was 96% (IQR, 79-111.5) in PASC patients. Hospitalized and critically ill patients had a significantly lower DLCO compared to ambulatory patients (P<0.001 for both . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. comparisons). The DLCO was significantly higher in ambulatory patients compared to healthy controls (P<0.001). Similar differences in spirometry, lung volumes and DLCO were found in our age-and BMI-adjusted multivariate analysis ( Figure S1 ).

Images from inspiratory and expiratory chest CT were available for analysis for 91 patients (91%). The most common abnormalities identified by qualitative analysis were air trapping (58%), GGO (51%), and pulmonary nodules (35%) ( Table 2) . Representative chest CT images demonstrating GGO, air trapping and architectural changes are shown in Figure S2 . Hospitalized and critically ill patients were more likely to have bronchiectasis and architectural distortion, honeycombing or scar compared to ambulatory patients. To more fully assess GGO and air trapping, quantitative analysis of chest CT images was performed and compared to healthy controls (Figure 3) . Among hospitalized and ICU patients, the mean percent of total lung classified as GGO was 13.2% and 28.7%, respectively, and was higher than in ambulatory patients (3.7%, P<0.001 for both comparisons). Although the amount of GGO observed in the ambulatory group was low, it was higher than healthy controls (0.06%; P<0.001). GGO as a percentage of total lung correlated with the percent predicted TLC (ρ = -0.6; P<0.001) and DLCO (ρ = -0.47; P<0.001). DPM analysis revealed that a substantial percentage of total lung was affected by air trapping in all severity groups, and there were no differences in the amount of air trapping across PASC groups. The mean percentage of total lung affected by air trapping was 25.4%, 34.5% and 27.2% in the ambulatory, hospitalized and ICU groups and was higher in ambulatory patients than in healthy controls (7.3%; P<0.001). These differences persisted after adjusting for age and BMI (Figure S3 ).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Air trapping can also be detected using lung volume measurements, specifically the RV to TLC ratio (RV/TLC). We therefore assessed RV/TLC using both plethysmography and quantitative CT.

Quantitative CT measurement of RV and TLC were obtained during the same effort from which air trapping was measured. The RV/TLC ratio was higher in the hospitalized group compared to the ambulatory group (P<0.01) by plethysmography (Figure 3 ) but was not different across groups when measured by quantitative CT (Figure S4) . RV/TLC calculated using plethysmography correlated with the presence of air trapping measured by DPM (ρ = 0.6; P<0.001) as did RV/TLC calculated using quantitative CT (ρ = 0.84; P<0.001).

Finally, we assessed whether there was a relationship between the severity of pulmonary function or CT abnormalities with time since acute infection or with respiratory symptoms. No significant correlations were found between spirometry, lung volumes, GGO or air trapping and days since diagnosis ( Figure S5) . PASC patients were separated by quartile using quantitative measures of GGO and air trapping, and the proportion of patients with dyspnea or cough in each quartile was assessed. There were no differences in the proportion of patients with respiratory symptoms across quartiles (Figure S6 ).

This prospective case series describes 100 patients with PASC. Patients were stratified by the highest level of care required during acute illness, and symptoms, pulmonary function testing and chest imaging were performed. As recently reported by others, persistent respiratory . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In contrast to most published reports of post-acute COVID-19, the majority of PASC patients in our cohort had mild disease during acute infection and did not require hospitalization.

Spirometry and lung volumes were normal in these patients and were not different than a cohort of healthy control subjects. We observed a higher DLCO in the ambulatory group compared to healthy controls. Increases in DLCO can be driven by increases in pulmonary capillary blood volume, as occurs in asthma and obesity 23 . Approximately a quarter of patients in the ambulatory group had asthma, and the BMI of the ambulatory group was significantly higher than healthy controls. Alternatively, increases in pulmonary capillary blood volume could be driven by endothelial dysfunction, as has been reported following SARS-CoV-2 infection 24,25 .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint Analysis of inspiratory and expiratory chest CT images, both by an experienced radiologist and using quantitative image analysis, revealed the presence of GGO and air trapping in ambulatory patients. Compared to hospitalized and critically ill patients, fewer patients in the ambulatory group had GGO on qualitative analysis of chest CT images and a smaller percentage of total lung was classified as GGO by texture analysis. Importantly, texture analysis revealed that GGO as a percentage of total lung was significantly higher in the ambulatory group compared to healthy controls, suggesting there is ongoing lung inflammation, edema or fibrosis in PASC patients. A striking proportion of patients in all three PASC groups had air trapping on qualitative CT analysis. The percent of total lung classified as air trapped using DPM analysis was not different across PASC groups, and there was significantly more air trapping measured by DPM in the ambulatory group compared to healthy controls. Air trapping occurs as a result of partial or complete airway obstruction in regions of the lung. We did not observe airflow obstruction by spirometry in any group, suggesting that air trapping in our cohort is due to involvement of small rather than large airways. Small airways, defined as non-cartilaginous airways with an internal diameter < 2mm, contribute little to total airway resistance and thus, small airway disease is typically not detected by spirometry until a large percentage (>75%) of all small airways are obstructed [26] [27] [28] . While small airways are not readily identified by lung imaging, a number studies have established the presence of air trapping on chest CT as a biomarker of functional small airways disease (fSAD) 19-21 . Taken together, our findings suggest that SARS-CoV-2 infection itself leads to fSAD and air trapping, while restrictive lung disease and impairment in gas exchange results from lung injury and ARDS, regardless of the underlying cause.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint

The angiotensin-converting enzyme 2 (ACE2) receptor, which facilitates SARS-CoV-2 infection, is expressed throughout the airway tract, including in the small airways 29, 30 . Thus, the fSAD observed in PASC patients (PASC-fSAD) could result from direct infection of the small airways by SARS-CoV-2, even in patients with mild acute infection. In this case, PASC-fSAD may result from an ongoing injury-repair process, cellular debris and/or abnormal mucus production.

Conversely, the immune response induced by SARS-CoV-2 could induce PASC-fSAD even in the absence of direct infection. Regardless of the underlying mechanism, the presence of fSAD months after the acute infection raises concern for airway remodeling and fibrosis. Of note, we did not observe a relationship between pulmonary function tests or quantitative CT measures of GGO or air trapping and time from diagnosis. The median time from diagnosis to pulmonary function measurements and chest CT imaging was approximately 75 days in our cohort.

Persistent respiratory abnormalities in this timeframe could represent a prolonged resolutionrepair process following SARS-CoV-2 infection and might therefore represent post-infectious bronchiolitis as has been described following other severe viral infections 31, 32 . However, small airways disease is also observed as a result of chronic inflammatory disorders such as connective tissue disease and inflammatory bowel disease, immunodeficiency, and following exposure to certain noxious stimuli 26 . In many of these cases, irreversible and sometimes progressive lung impairment is observed. Given the prevalence of PASC among COVID-19 survivors and the proportion of patients that appear to be affected by PASC-fSAD, longitudinal studies aimed at understanding the natural history of disease should be pursued.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021 We did not observe a correlation between dyspnea and the severity of either GGO or air trapping measured by quantitative CT analysis. This is perhaps not surprising given the relatively small number of patients in our cohort and might suggest that in addition to fSAD, other pathological processes contribute to the respiratory symptoms frequently observed in PASC. Extra-pulmonary involvement, including increased cardiometabolic demand, exertional tachycardia, chronic fatigue and anxiety, have been reported in patients with PASC 33 . Further studies will be needed to more fully understand the mechanisms contributing to dyspnea in post-COVID-19 patients.

LIMITATIONS This is single center study, and thus the generalizability of our findings may be limited.

Furthermore, we only evaluated symptomatic patients, and therefore cannot comment on the prevalence of lung function and imaging abnormalities among all COVID-19 survivors.

Longitudinal assessment will be required to determine whether PASC-fSAD improves over time, or whether it leads to persist or progressive lung disease.

Our study demonstrates that patients with PASC have a high prevalence of long-lasting air trapping by imaging, regardless of the initial severity of infection. Air trapping is often missed with spirometry but can be detected using inspiratory and expiratory CT imaging and plethysmography. Studies aimed at determining the natural history of PASC-fSAD and the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint biological mechanisms that underlie these findings are urgently needed in order to identify therapeutic and preventative interventions. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Tables   Table 1: Demographic and clinical characteristics of the patients at baseline . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Pleural effusion 0/91(0%) 0/59(0%) 0/16 (0%) 0/16 (0%) Imaging data is not available for 8 ambulatory patients and 1 hospitalized patient. **P<0.01 and ***P<0.001 compared to ambulatory patients.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 30, 2021. ; https://doi.org/10.1101/2021.05.27.21257944 doi: medRxiv preprint

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Lung Function Deficits and Symptom Burden in Survivors of COVID-19 Requiring Mechanical Ventilation

Quality of Life, Pulmonary Function, and Tomographic Scan Abnormalities After ARDS

Changes in lung parenchyma after acute respiratory distress syndrome (ARDS): assessment with highresolution computed tomography

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

Follow-up chest radiographic findings in patients with MERS-CoV after recovery

Management of post-acute covid-19 in primary care

for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19

Significance of Respiratory Symptoms and the Diagnosis of Chronic Bronchitis in a Working Population

Pulmonary function and health-related quality of life after COVID-19 pneumonia

Quantitative CT imaging and advanced visualization methods: potential application in novel coronavirus disease 2019 (COVID-19) pneumonia

QIBA guidance: Computed tomography imaging for COVID-19 quantitative imaging applications

Interstitial Lung Disease: A Quantitative Study Using the Adaptive Multiple Feature Method

Quantification of Pulmonary Emphysema from Lung Computed Tomography Images

Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation

Small airways diseases, excluding asthma and COPD: an overview

Pathophysiology of airflow limitation in chronic obstructive pulmonary disease

The Relations between Structural Changes in Small Airways and Pulmonary-Function Tests

Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis

Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in the human respiratory tract

Bronchopneumonia with Serious Sequelae in Children with Evidence of Adenovirus Type 21 Infection

Respiratory Syncytial Virus Infection in Adults: Clinical, Virologic, and Serial Pulmonary Function Studies

Post-acute COVID-19 syndrome

Imaging of COVID-19 pneumonia: Patterns, pathogenesis, and advances

The authors would like to acknowledge the patients who participated in this study. We also thank Kimberly Sprenger, Sue Ellen Salisbury, Maria Aguilar Pescozo, Deborah O'Connell-Moore, and Jarron Atha for their assistance with this study. The authors would also like to